Pzena Investment Management LLC Buys 34,030 Shares of Pfizer Inc. $PFE

Pzena Investment Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 0.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,958,922 shares of the biopharmaceutical company’s stock after purchasing an additional 34,030 shares during the period. Pzena Investment Management LLC owned 0.10% of Pfizer worth $143,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of PFE. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer during the 2nd quarter worth approximately $26,000. HFM Investment Advisors LLC lifted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. lifted its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE PFE opened at $28.00 on Friday. The company has a market cap of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock’s fifty day moving average price is $25.30 and its 200 day moving average price is $26.25. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s payout ratio is 226.32%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PFE shares. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC cut Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Finally, Guggenheim lowered their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.28.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.